| PubMed | Title | Journal | Year | Linked by |
|---|
| PMID 40785174 | A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy. | Current gene therapy | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 41198051 | Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy. | Blood | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 41274843 | Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms. | Blood reviews | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 41448545 | Overview of gene therapy for hemophilia: questions and answers to navigate the innovation. | Journal of thrombosis and haemostasis : JTH | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 41549917 | Balancing Promise and Peril: Hemophilia Gene Therapy Insights. | IUBMB life | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 41709782 | Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis. | Expert review of hematology | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 41773269 | Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders. | Journal of blood medicine | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 41988906 | Bringing Gene Therapy Into Real World Clinical Practice. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 42049028 | From early promise to market withdrawal of valoctocogene roxaparvovec. | Molecular therapy : the journal of the American Society of Gene Therapy | 2026 | name in title: valoctocogene roxaparvovec |
| PMID 42061679 | Correlation between Factor VIII chromogenic activity and antigen levels in patients treated with adeno-associated virus 5-mediated gene therapy for hemophilia A. | Journal of thrombosis and haemostasis : JTH | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 42232249 | Real-world provider experiences with hemophilia A gene therapy: administration of valoctocogene roxaparvovec. | Research and practice in thrombosis and haemostasis | 2026 | name in title: valoctocogene roxaparvovec |
| PMID 42290228 | Italian Patients Journey for Gene Therapy in Haemophilia A. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 42389809 | Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec. | Haematologica | 2026 | name in title: valoctocogene roxaparvovec |
| PMID 42432779 | Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials. | Trials | 2026 | name in abstract: Roctavian |
| PMID 42662499 | Roctavian withdrawal: exploring the gap between innovation and healthcare system readiness in hemophilia A gene therapy. | Research and practice in thrombosis and haemostasis | 2026 | name in title: Roctavian |
| PMID 42676001 | Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 42784360 | Impact of Gene Therapy on the Haemophilia-Free Mind: Outcomes Before and After Valoctocogene Roxaparvovec in GENEr8-1 Trial Participants. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in title: valoctocogene roxaparvovec |
| PMID 42947409 | Arthroplasty After Hemophilia Gene Therapy: Perioperative Implications and Clinical Experience. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 42976908 | Patient-Relevant Questions on Gene Therapy for Haemophilia. | Hamostaseologie | 2026 | name in abstract: valoctocogene roxaparvovec |
| PMID 38588706 | Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives. | Seminars in thrombosis and hemostasis | 2025 | name in abstract: valoctocogene roxaparvovec |
| PMID 40090623 | Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. | Journal of thrombosis and haemostasis : JTH | 2025 | name in title: valoctocogene roxaparvovec |
| PMID 40091689 | A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis. | Expert review of hematology | 2025 | name in title: valoctocogene roxaparvovec |
| PMID 40156191 | The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in abstract: Roctavian |
| PMID 40464094 | Recombinant Adeno-Associated Virus Integration Profiles in Nonhuman Primates and Gene Therapy Participants after Treatment with Valoctocogene Roxaparvovec. | Human gene therapy | 2025 | name in title: valoctocogene roxaparvovec |
| PMID 40488175 | Gene-based therapies for hemophilia. | Research and practice in thrombosis and haemostasis | 2025 | name in abstract: valoctocogene roxaparvovec |
| PMID 40868273 | Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context. | Biomedicines | 2025 | name in abstract: Roctavian |
| PMID 40916408 | Advances in Gene Therapy Clinical Trials for Hemophilia Care. | Current gene therapy | 2025 | name in abstract: valoctocogene roxaparvovec |
| PMID 40924278 | Comparative Effectiveness of Valoctocogene Roxaparvovec and Efanesoctocog Alfa in the Treatment of Severe Hemophilia A: A Matching-Adjusted Indirect Comparison of Bleeding Frequency. | Advances in therapy | 2025 | name in title: valoctocogene roxaparvovec |
| PMID 41127589 | Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review. | Frontiers in public health | 2025 | name in abstract: valoctocogene roxaparvovec |
| PMID 41348030 | Deconstructing gene therapy in hemophilia for the clinician. | Hematology. American Society of Hematology. Education Program | 2025 | name in abstract: valoctocogene roxaparvovec |
| PMID 41362291 | Nonclinical toxicity study duration in AAV gene therapy development: Evidence from industry survey supports adequacy of short-term assessments. | Molecular therapy. Methods & clinical development | 2025 | name in abstract: Roctavian |
| PMID 37978816 | Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B. | The Annals of pharmacotherapy | 2024 | name in title: valoctocogene roxaparvovec |
| PMID 37989969 | Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. | PharmacoEconomics | 2024 | name in abstract: valoctocogene roxaparvovec |
| PMID 38684460 | Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A. | Haemophilia : the official journal of the World Federation of Hemophilia | 2024 | name in title: valoctocogene roxaparvovec |
| PMID 38764998 | Valoctocogene Roxaparvovec. | Hospital pharmacy | 2024 | name in title: valoctocogene roxaparvovec |
| PMID 38845160 | Evaluation of one-stage and chromogenic assays for the laboratory measurement of factor VIII activity following valoctocogene roxaparvovec infusion. | Haemophilia : the official journal of the World Federation of Hemophilia | 2024 | name in title: valoctocogene roxaparvovec |
| PMID 38991118 | Roctavian gene therapy for hemophilia A. | Blood advances | 2024 | name in title: Roctavian |
| PMID 39104575 | The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice. | Molecular therapy. Methods & clinical development | 2024 | name in abstract: valoctocogene roxaparvovec |
| PMID 39136120 | Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experience. | Haemophilia : the official journal of the World Federation of Hemophilia | 2024 | name in title: valoctocogene roxaparvovec |
| PMID 39226466 | Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice. | Blood advances | 2024 | name in title: valoctocogene roxaparvovec |
| PMID 39242221 | [Marketing authorisation for rare diseases: The European regulatory perspective using the example of gene and cell therapies]. | Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen | 2024 | name in abstract: Roctavian |
| PMID 39321118 | A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B. | Journal of managed care & specialty pharmacy | 2024 | name in abstract: valoctocogene roxaparvovec |
| PMID 39339243 | Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B. | Pharmaceutics | 2024 | name in abstract: valoctocogene roxaparvovec |
| PMID 39687929 | Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial. | Research and practice in thrombosis and haemostasis | 2024 | name in title: valoctocogene roxaparvovec |
| PMID 39712873 | Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial. | Therapeutic advances in hematology | 2024 | name in abstract: valoctocogene roxaparvovec |
| PMID 35132205 | Lack of germline transmission in male mice following a single intravenous administration of AAV5-hFVIII-SQ gene therapy. | Gene therapy | 2023 | name in abstract: valoctocogene roxaparvovec |
| PMID 36696462 | Valoctocogene roxaparvovec gene transfer in participants with HIV. | Blood advances | 2023 | name in title: valoctocogene roxaparvovec |
| PMID 37347645 | Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. | Haemophilia : the official journal of the World Federation of Hemophilia | 2023 | name in title: valoctocogene roxaparvovec |
| PMID 37353081 | Hemophilia gene therapy: first, do no harm. | Journal of thrombosis and haemostasis : JTH | 2023 | name in abstract: valoctocogene roxaparvovec |
| PMID 37490225 | Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2023 | name in abstract: valoctocogene roxaparvovec |
| PMID 37590493 | BioMarin's ROCTAVIAN Wins Food and Drug Administration Approval As First Gene Therapy for Severe Hemophilia A. | Human gene therapy | 2023 | name in title: Roctavian |
| PMID 37672530 | Hemophilia Gene Therapy: The End of the Beginning? | Human gene therapy | 2023 | name in abstract: valoctocogene roxaparvovec |
| PMID 37755692 | Valoctocogene roxaparvovec (Roctavian) - a gene therapy for severe hemophilia A. | The Medical letter on drugs and therapeutics | 2023 | name in title: valoctocogene roxaparvovec |
| PMID 38462459 | Viral Vectors in Gene Replacement Therapy. | Biochemistry. Biokhimiia | 2023 | name in abstract: Roctavian |
| PMID 34421119 | Ultra-sensitive AAV capsid detection by immunocapture-based qPCR following factor VIII gene transfer. | Gene therapy | 2022 | name in abstract: valoctocogene roxaparvovec |
| PMID 35036471 | Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers. | Molecular therapy. Methods & clinical development | 2022 | name in abstract: valoctocogene roxaparvovec |
| PMID 35141470 | Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A. | HemaSphere | 2022 | name in abstract: valoctocogene roxaparvovec |
| PMID 35782594 | Application of in-vitro-cultured primary hepatocytes to evaluate species translatability and AAV transduction mechanisms of action. | Molecular therapy. Methods & clinical development | 2022 | name in abstract: valoctocogene roxaparvovec |
| PMID 36082993 | Liver Gene Therapy. | Human gene therapy | 2022 | name in abstract: valoctocogene roxaparvovec |
| PMID 36092364 | Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood. | Molecular therapy. Methods & clinical development | 2022 | name in abstract: valoctocogene roxaparvovec |
| PMID 36142153 | The Arrival of Gene Therapy for Patients with Hemophilia A. | International journal of molecular sciences | 2022 | name in abstract: valoctocogene roxaparvovec |
| PMID 36214970 | Valoctocogene Roxaparvovec: First Approval. | Drugs | 2022 | name in title: valoctocogene roxaparvovec |
| PMID 36485127 | Gene therapy for hemophilia. | Hematology. American Society of Hematology. Education Program | 2022 | name in abstract: valoctocogene roxaparvovec |
| PMID 39086961 | Strategies to improve safety profile of AAV vectors. | Frontiers in molecular medicine | 2022 | name in abstract: Roctavian |
| PMID 33309883 | Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A. | Molecular therapy : the journal of the American Society of Gene Therapy | 2021 | name in title: valoctocogene roxaparvovec |
| PMID 33908280 | The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors. | Journal of managed care & specialty pharmacy | 2021 | name in title: valoctocogene roxaparvovec |
| PMID 31890737 | Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec. | Molecular therapy. Methods & clinical development | 2020 | name in title: valoctocogene roxaparvovec |
| PMID 31971453 | Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. | Journal of medical economics | 2020 | name in abstract: valoctocogene roxaparvovec |
| PMID 32775496 | Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter. | Molecular therapy. Methods & clinical development | 2020 | name in abstract: valoctocogene roxaparvovec |
| PMID 31193016 | The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy. | Molecular therapy. Methods & clinical development | 2019 | name in abstract: valoctocogene roxaparvovec |
| PMID 29292164 | Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice. | Molecular therapy : the journal of the American Society of Gene Therapy | 2018 | name in title: BMN 270 |